Ombrabulin Explained

Ombrabulin was an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis.[1] Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth.[2] [3]

It was granted orphan drug status by the European Medicines Agency in April 2011.[4]

In January 2013, Sanofi said it discontinued development of ombrabulin after disappointing results from phase III clinical trials.[5]

Notes and References

  1. Web site: Ombrabulin (AVE8062) . Sanofi-Aventis Oncology.
  2. 10551334 . 5926172 . 1999 . Hori . K . Saito . S . Nihei . Y . Suzuki . M . Sato . Y . Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700 . 90 . 9 . 1026–38 . Japanese Journal of Cancer Research . 10.1111/j.1349-7006.1999.tb00851.x.
  3. 12085211 . 2002 . Hori . K . Saito . S . Kubota . K . A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs . 86 . 10 . 1604–14 . 10.1038/sj.bjc.6600296 . 2746587 . British Journal of Cancer.
  4. Web site: Orphan Designation EU/3/11/853 . European Medicines Agency . 15 April 2011.
  5. News: Sanofi has 65 new compounds in development, says R&D chief.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ombrabulin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.